Losartan Potassium Tablet, Film Coated
Product Images NDC 43063-854

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 43063-854). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (43063854)

Label for Losartan Potassium USP 50 mg film-coated tablets, containing 90 tablets. The label includes the NDC 43063-854-90, manufacturer PD-Rx Pharmaceuticals, Inc. of Oklahoma City, OK. It provides dosage instructions fields, storage warnings, lot number E22E21, and expiration date 11/2023. The label has bilingual text in English and Spanish and features a barcode and QR code.*

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over 60 study months for Atenolol and Losartan potassium. The graph shows two trend lines—dotted for Atenolol and solid for Losartan potassium—with an adjusted risk reduction of 13% (p=0.021) indicated below the x-axis. The x-axis represents study months, and the y-axis shows the percentage of patients with the primary endpoint.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of up to 66 months. Two lines represent patients taking Atenolol and Losartan Potassium, showing a lower percentage of stroke patients in the Losartan Potassium group. The graph includes an adjusted risk reduction value of 25% with a statistical significance (p=0.001).*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

Figure showing hazard ratios with 95% confidence intervals for primary composite and stroke events by demographic subgroups comparing Losartan Potassium and Atenolol event rates. Data includes overall and subgroups by age, gender, race, isolated systolic hypertension, diabetes, and cardiovascular disease history among patients.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with events over time in months for Losartan Potassium versus placebo. The graph indicates a risk reduction of 16.1% with a p-value of 0.022, showing cumulative event rates up to 48 months.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium showing its molecular framework including the characteristic functional groups and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.